Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D H Miller

Showing results (411-420 of 768) with videos related to

Pageof 77
Sort By:
Neurology|February 1, 1988
Magnetic resonance imaging of the optic nerve in optic neuritisD H Miller, M R Newton, J C van der Poel, et al.
Journal of Neurology|December 4, 2003
High field MRI correlates of myelin content and axonal density in multiple sclerosis--a post-mortem study of the spinal cordJ P Mottershead, K Schmierer, M Clemence, et al.
Neurology|January 27, 1998
Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritisR Kapoor, D H Miller, S J Jones, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 10, 2009
Primary progressive multiple sclerosis diagnostic criteria: a reappraisalX Montalban, J Sastre-Garriga, M Filippi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 16, 2000
One year follow up study of primary and transitional progressive multiple sclerosisV L Stevenson, D H Miller, S M Leary, et al.
Neurology|January 8, 2010
MRI criteria for MS in patients with clinically isolated syndromesX Montalban, M Tintoré, J Swanton, et al.
Neurology|January 5, 2002
The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MSP A Brex, P D Molyneux, P Smiddy, et al.
Journal of Neurology|October 22, 2010
BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosisD G MacManus, D H Miller, L Kappos, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 7, 2002
Two-year follow-up study of primary and transitional progressive multiple sclerosisG T Ingle, V L Stevenson, D H Miller, et al.
Neurology|August 19, 2011
Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndromeH-P Hartung, M S Freedman, C H Polman, et al.
Pageof 77

Showing results (411-420 of 768) with videos related to

Sort By:
Pageof 77
Neurology|February 1, 1988
Magnetic resonance imaging of the optic nerve in optic neuritisD H Miller, M R Newton, J C van der Poel, et al.
Journal of Neurology|December 4, 2003
High field MRI correlates of myelin content and axonal density in multiple sclerosis--a post-mortem study of the spinal cordJ P Mottershead, K Schmierer, M Clemence, et al.
Neurology|January 27, 1998
Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritisR Kapoor, D H Miller, S J Jones, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 10, 2009
Primary progressive multiple sclerosis diagnostic criteria: a reappraisalX Montalban, J Sastre-Garriga, M Filippi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 16, 2000
One year follow up study of primary and transitional progressive multiple sclerosisV L Stevenson, D H Miller, S M Leary, et al.
Neurology|January 8, 2010
MRI criteria for MS in patients with clinically isolated syndromesX Montalban, M Tintoré, J Swanton, et al.
Neurology|January 5, 2002
The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MSP A Brex, P D Molyneux, P Smiddy, et al.
Journal of Neurology|October 22, 2010
BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosisD G MacManus, D H Miller, L Kappos, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 7, 2002
Two-year follow-up study of primary and transitional progressive multiple sclerosisG T Ingle, V L Stevenson, D H Miller, et al.
Neurology|August 19, 2011
Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndromeH-P Hartung, M S Freedman, C H Polman, et al.
Pageof 77